Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1

Oncogene

Volumn 32, Issue 1, 2013, Pages 70-77

  Gulzar, Z G ^a   Mckenney, J K ^a   Brooks, J D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E2F1; gene expression profiling; NuSAP; prostate cancer; recurrence

Indexed keywords

CCAAT BINDING FACTOR; COMPLEMENTARY DNA; NUSAP PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER RECURRENCE; CANCER SURVIVAL; CELL INVASION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

BASE SEQUENCE; CELL LINE, TUMOR; DNA, COMPLEMENTARY; E2F1 TRANSCRIPTION FACTOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RECURRENCE; RNA, MESSENGER;

EID: 84872005460     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.27     Document Type: Article

References (51)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
3. Roobol MJ, Kerkhof M, Schroder FH, Cuzick J, Sasieni P, Hakama M et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-591.
4. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-826.
5. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007; 67: 8504-8510.
6. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 2002; 62: 4499-4506.
7. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML et al. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 2001; 61: 4683-4688.
8. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33: 25-35.
9. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1: 203-209.
10. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
11. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 5974-5978.
12. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439.
13. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al. CYP2D6 gene variants: Association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010; 12: R64.
14. Amemiya H, Menolascino F, Pena A. Role of the expression of c-Met receptor in the progression of gastric cancer. Invest Clin 2010; 51: 369-380.
15. Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE et al. Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 2011; 121: 402-406.
16. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007; 67: 547-556.
17. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106.
18. Chotteau-Lelievre A, Revillion F, Lhotellier V, Hornez L, Desbiens X, Cabaret V et al. Prognostic value of ERM gene expression in human primary breast cancers. Clin Cancer Res 2004; 10: 7297-7303.
19. Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 2007; 14: 245-256.
20. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod Pathol 2010; 23: 1605-1615.
21. Helfenstein A, Frahm SO, Krams M, Drescher W, Parwaresch R, Hassenpflug J. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: Distinction from enchondroma and identification of progressive tumors. Am J Clin Pathol 2004; 122: 912-918.
22. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM et al. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 2008; 14: 1734-1743.
23. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 2010; 103: 765-771.
24. Miyata Y, Sakai H, Kanda S, Igawa T, Hayashi T, Kanetake H. Expression of insulinlike growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Urology 2004; 63: 1184-1190.
25. Monge M, Colas E, Doll A, Gil-Moreno A, Castellvi J, Diaz B et al. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 2009; 30: 1288-1297.
26. Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res 2007; 67: 2893-2898.
27. Mustjoki S, Hernesniemi S, Rauhala A, Kahkonen M, Almqvist A, Lundan T et al. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica 2009; 94: 1469-1471.
28. Schrader C, Janssen D, Klapper W, Siebmann JU, Meusers P, Brittinger G et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma. Br J Cancer 2005; 93: 939-945.
29. Setoguchi T, Kikuchi H, Yamamoto M, Baba M, Ohta M, Kamiya K et al. Microarray analysis identifies versican and CD9 as potent prognostic markers in gastric gastrointestinal stromal tumors. Cancer Sci 2011; 102: 883-889.
30. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009; 124: 644-652.
31. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663.
32. Yuan RH, Jeng YM, Pan HW, Hu FC, Lai PL, Lee PH et al. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clin Cancer Res 2007; 13 (Pt 1): 5368-5376.
33. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 2009; 106: 20429-20434.
34. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113: 913-923.
35. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
36. Fujiwara T, Harigae H, Okitsu Y, Takahashi S, Yokoyama H, Yamada MF et al. Expression analyses and transcriptional regulation of mouse nucleolar spindleassociated protein gene in erythroid cells: Essential role of NF-Y. Br J Haematol 2006; 135: 583-590.
37. Hussain S, Benavente SB, Nascimento E, Dragoni I, Kurowski A, Gillich A et al. The nucleolar RNA methyltransferase Misu (NSun2) is required for mitotic spindle stability. J Cell Biol 2009; 186: 27-40.
38. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res 2006; 66: 11897-11906.
39. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K et al. A trimarker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One 2011; 6: E20293.
40. Adamo B, Anders CK. Stratifying triple-negative breast cancer: Which definition(s) to use? Breast Cancer Res 2011; 13: 105.
41. Rodriguez-Enriquez S, Pacheco-Velazquez SC, Gallardo-Perez JC, Marin-Hernandez A, Aguilar-Ponce JL, Ruiz-Garcia E et al. Multi-biomarker pattern for tumor identification and prognosis. J Cell Biochem 2011; 112: 2703-2715.
42. von Euler H, Eriksson S. Comparative aspects of the proliferation markerthymidine kinase 1 in human and canine tumour diseases. Vet Comp Oncol 2011; 9: 1-15.
43. Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin PC et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011; 21: 56-67.
44. Wadia PP, Coram M, Armstrong RJ, Mindrinos M, Butte AJ, Miklos DB. Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood 2010; 115: 2077-2087.
45. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120: 4478-4492.
46. Iyer J, Moghe S, Furukawa M, Tsai MY. What's Nu(SAP) in mitosis and cancer? Cell Signal 2011; 23: 991-998.
47. Vanden Bosch A, Raemaekers T, Denayer S, Torrekens S, Smets N, Moermans K et al. NuSAP is essential for chromatin-induced spindle formation during early embryogenesis. J Cell Sci 2010; 123 (Pt 19): 3244-3255.
48. Lapointe J, Li C, Higgins JP, van de RM, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
49. Kim YH, Pollack Jr. Comparative genomic hybridization on spotted oligonucleotide microarrays. Methods Mol Biol 2009; 556: 21-32.
50. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight SS et al. The Stanford Microarray Database. Nucleic Acids Res 2001; 29: 152-155.
51. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567- 6572.